Atreca, Inc., announced today that it has entered into a strategic collaboration with a Top 10 global pharmaceutical company in which Atreca will apply its Immune Repertoire Capture™ technology to infectious disease programs.
“Atreca’s proprietary technology rapidly and robustly delivers the set of native, functional antibodies generated in the human immune response to a vaccine or pathogen,” said Tito A. Serafini, Ph.D., chief executive officer and co-founder of Atreca, Inc. “We are pleased that this collaboration demonstrates once again the value Atreca brings to the search for more effective medicines for infectious disease.”
Under the terms of the agreement, Atreca will receive monetary compensation for its role in the collaboration. In addition, the pharmaceutical company partner will make an investment in Atreca and receive an option right for further investment.
Immune Repertoire CaptureTM technology employs proprietary molecular biology and informatics and leverages next-generation sequencing to identify, rapidly and comprehensively, the set of functional antibodies produced during an immune response. These antibodies both have utility themselves and can be employed to identify the targets of an immune response. Applied to human disease, Immune Repertoire CaptureTM is an engine for the discovery and development of antibodybased therapeutics, vaccines, diagnostics, and research reagents.
Atreca, Inc., is a privately held biopharmaceutical company whose Immune Repertoire CaptureTM technology revolutionizes the discovery and development of a wide range of products. The Company was founded in 2010 and has its headquarters in San Carlos, California.
For additional information, please visit: www.atreca.com.